FDA "Grids" for More Transparent Risk-Benefit Decision

FDA is designing a five-item grid as a management tool to explain its risk-benefit decisions in a new more concise format. The model that it has created as a working template confirms a truism about its drug approval tendencies that industry has suspected for years: the baseline for FDA approval is a high-rating of the severity of the disease being treated and the medical need for the product.

By Cole Werble

The severity of a medical condition and the need for a new treatment lead the list of factors the Food...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet